Welcome to our dedicated page for Cooper SEC filings (Ticker: COO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CooperCompanies, Inc. (Nasdaq: COO) files a range of documents with the U.S. Securities and Exchange Commission that provide detail on its operations as a global medical device company. These SEC filings cover its two business units, CooperVision and CooperSurgical, and include information on revenue, segment performance, margins, cash flow, and significant corporate actions.
On this page, you can review annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which typically present consolidated financial statements, segment data for CooperVision and CooperSurgical, discussions of non‑GAAP measures, and explanations of items such as acquisition and integration‑related charges, business optimization charges, and product line exits. These filings also describe how the company defines and uses metrics like constant currency revenue growth, organic revenue growth, and free cash flow.
Current reports on Form 8‑K provide timely updates on material events, such as quarterly earnings releases, changes in executive responsibilities, and governance developments. For example, recent 8‑K filings have addressed the reporting of quarterly financial results and the assumption of principal accounting officer responsibilities by the company’s Chief Financial Officer. Proxy statements referenced in these filings contain biographical and governance information about directors and senior executives.
Stock Titan enhances access to COO filings by offering AI‑powered summaries that explain key sections of lengthy documents in plain language. Real‑time updates from EDGAR ensure that new 10‑K, 10‑Q, and 8‑K filings appear quickly, while insider transaction reports on Form 4, when available, can be used to monitor trading activity by officers and directors. These tools help users navigate CooperCompanies’ regulatory disclosures more efficiently and understand the financial and governance details that shape the company’s performance.
Cooper Companies, Inc. ownership filing amended: The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0%. The amendment explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, with disaggregated reporting by subsidiaries. filing signed March 26, 2026.
The Cooper Companies reported higher quarterly sales and profit for the three months ended January 31, 2026. Net sales rose to $1,024.1 million from $964.7 million, driven mainly by growth in CooperVision contact lenses and steady gains in CooperSurgical office, surgical, and fertility products.
Net income increased to $130.8 million from $104.3 million, with diluted earnings per share up to $0.66 from $0.52. CooperVision delivered operating income of $210.2 million and CooperSurgical $26.8 million, as overall operating margin improved to 21%. Operating cash flow strengthened to $260.9 million, supporting $102.2 million of capital spending and $92.5 million of share repurchases.
The company ended the quarter with total assets of $12,424.2 million and total debt of $2,499.7 million. Subsequent amendments extended the maturity of $950.0 million of term loans to 2031. Cooper also disclosed a U.K. payroll tax dispute with a reasonably possible loss range of £0–£71.7 million, plus interest, for which no liability has been recorded.
CooperCompanies reported a solid fiscal first quarter 2026, with revenue of $1.024 billion, up 6% from a year earlier and 3% organically. Growth was led by CooperVision, where revenue rose 8% to $695.1 million, while CooperSurgical revenue increased 3% to $329.0 million.
GAAP diluted EPS grew to $0.66, up 27%, and non-GAAP diluted EPS rose to $1.10, up 20%, as operating margin improved to 21% on a GAAP basis and 27% on a non-GAAP basis. Free cash flow was $158.7 million, supporting $92.5 million of share repurchases. The company raised its fiscal 2026 outlook, guiding total revenue to $4.306–$4.346 billion, non-GAAP EPS to $4.58–$4.66, and free cash flow to $600–$625 million.
CooperCompanies presents its 2026 annual meeting proxy, highlighting 2025 results, governance and executive pay. Stockholders are asked to elect nine directors, ratify KPMG as auditor, and approve a non-binding say-on-pay vote, with the Board recommending “FOR” on all three proposals.
In fiscal 2025, revenue reached $4.09 billion, up 5% from 2024, with GAAP diluted EPS of $1.87, non-GAAP diluted EPS of $4.13, and free cash flow of about $434 million. The company repurchased $290.1 million of stock, roughly 4.1 million shares, and the Board expanded the share repurchase authorization to $2 billion, leaving nearly $1 billion available.
Cooper completed major restructuring and integration work, recording approximately $89 million in related charges and expecting about $50 million in annual pre-tax savings from fiscal 2026. The proxy emphasizes an independent Board, robust committee structure, strong ESG and cybersecurity oversight, and a pay-for-performance program where most executive compensation is performance-based.
CooperCompanies executive Brian G. Andrews, EVP, CFO & Treasurer, reported an amended stock option award. The filing corrects the number of shares issuable under a previously reported option grant to 41,563 shares of common stock at an exercise price of $99.08 per share.
The options were granted on 12/10/2024, are held directly, and expire on 12/10/2034. They vest at 25% per year over four years starting on the grant date, reflecting time-based equity compensation rather than an open-market stock purchase or sale.
Cooper Companies’ President & CEO, who is also a director, received a grant of stock options covering 184,069 shares of common stock on 12/10/2024. The options have an exercise price of $99.08 and expire on 12/10/2034.
The Form 4/A states it is filed solely to correct the number of shares issuable upon exercise of this previously reported option grant. The options vest at 25% per year over four years beginning on the grant date, and the full 184,069 options are reported as directly beneficially owned.
The Cooper Companies, Inc. amended its debt agreements to adjust terms on its term loan and revolving credit facilities. The company extended the maturity of $950 million of term loans to February 3, 2031, while keeping the maturity date for the remaining $550 million of term loans unchanged.
The amendment also removes the prior credit spread adjustment and raises the cap on incremental term loans to the greater of $1.365 billion and 100% of consolidated EBITDA. Pricing on the term loans can now be based either on the company’s non-credit enhanced, senior unsecured long-term debt ratings or on its consolidated net indebtedness to consolidated EBITDA ratio.
A related amendment to the revolving credit agreement aligns its provisions with the revised term loan agreement, including the removal of credit spread adjustments.
Cooper Companies director Colleen Jay reported exercising stock options and increasing her direct shareholdings. On 01/12/2026, she exercised 7,064 stock options with an exercise price of $39.4 per share, converting them into the same number of shares of Common Stock.
Following this transaction, she directly held 36,585 shares of Common Stock. The exercised stock option award was fully used, leaving 0 derivative securities of that option grant outstanding.
Cooper Companies, Inc. director Walter M. Rosebrough Jr. filed an initial statement of beneficial ownership, reporting indirect control over 10,000 shares of common stock as of 01/03/2026. These shares are held by the Walter M Rosebrough, Jr Revocable Trust, for which he serves as sole trustee, so the position is reported as indirectly owned rather than held in his own name. The filing does not show any recent stock purchase or sale, only the existing ownership position.
Cooper Companies, Inc. (COO) reported insider equity transactions by President & CEO and director Albert G. White III. On 01/08/2026, 18,340 restricted stock units were converted into common stock at an exercise price of $0.00 per share, increasing his directly held common stock to 254,491 shares. On the same date, he disposed of 9,419 common shares at a price of $83.13 per share, leaving 245,072 common shares directly owned after the transactions. Following these events, he also held 36,676 restricted stock units, which vest annually over four years, subject to continued service, with no stated expiration date.